Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis
- 24 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 66 (11), 3929-3937
- https://doi.org/10.1007/s10620-021-06872-z
Abstract
Background Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients. However, it remains controversial whether it is effective in treating COVID-19. Aims This study aimed to explore whether famotidine use is associated with reduced risk of the severity, death, and intubation for COVID-19 patients. Methods This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42020213536). A comprehensive search was performed to identify relevant studies up to October 2020. I-squared statistic and Q-test were utilized to assess the heterogeneity. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated through the random effects or fixed effects model according to the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also conducted. Results Five studies including 36,635 subjects were included. We found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients (pooled RR was 0.82, 95% CI = 0.52–1.30, P = 0.40). Conclusion Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.Keywords
This publication has 49 references indexed in Scilit:
- Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysisBMJ, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Histamine‐induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMPBritish Journal of Pharmacology, 2004
- Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS DrugsScience, 2003
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Inhibition by Histamine of Platelet-Activating-Factor-Induced Neutrophil Chemotaxis in Bronchial AsthmaInternational Archives of Allergy and Immunology, 1989
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- In vitro Effects of Histamine on Eosinophil MigrationInternational Archives of Allergy and Immunology, 1980